Regenxbio

Yahoo Finance • 8 months ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the t... Full story

Yahoo Finance • 9 months ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Kenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. Regenxbio Inc is a biotechnology company focused on the development, c... Full story

Yahoo Finance • 10 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to RE... Full story

Yahoo Finance • 10 months ago

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest priority programs are ABBV-RGX-314 for the... Full story

Yahoo Finance • 2 years ago

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter and full year e... Full story

Yahoo Finance • 2 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duch... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. 41st Annual J.P. Morgan Healthcare Conferen... Full story

Yahoo Finance • 2 years ago

Rockville's RegenxBio lays out potential path to market for its first gene therapy treatments

For RegenxBio Inc., a Rockville biotech that's made millions from royalty revenue over the years, 2023 will be critical to its ability to start selling its own commercial product for the first time. The 13-year-old company, which went publ... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022: Panel: Unique Delivery Te... Full story

Yahoo Finance • 2 years ago

REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 20... Full story

Yahoo Finance • 2 years ago

Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appoint... Full story

Yahoo Finance • 2 years ago

Jennifer Zachary Joins REGENXBIO Board of Directors

ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022. Ms. Zachary will serve as a member of REGENXBIO's Audit Commi... Full story